SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Art Pappas will moderate and lead a discussion entitled "Are we Heading into a Pharmaceutical and Biotechnology Market of Orphan and Narrow Indications" at the 2012 BIO International Convention on June 19th in Boston, MA.
News | 02. 29. 2012
Art Pappas will moderate and lead a discussion entitled "Are we Heading into a Pharmaceutical and Biotechnology Market of Orphan and Narrow Indications" at the 2012 BIO International Convention on June 19th in Boston, MA.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.